Objective
Atherosclerosis, the major cause of cardiovascular disease (CVD) is an inflammatory disease, where the immune system plays an important role. Novel autoantibodies as protection or risk markers and therapy through immunomodulation could be a major advance in prevention and treatment of CVD. One example is natural antibodies against phosphorylcholine (aPC), an antigen exposed in some bacteria and in phospholipids with platelet activating factor (PAF)-activity, e g in oxidized LDL. Our clinical and experimental studies indicate that aPC, mainly of IgM type protect against atherosclerosis and CVD. Risk markers are thrombogenic antiphospholipid antibodies (aPL), and our main focus is novel types of aPL against platelet activating factor (PAF) or PAF-like lipids (aPAF). In a prototypic autoimmune disease, SLE, such aPL are raised and the risk of CVD is very high. Closely associated with these markers are our novel therapeutic principles. One is to raise the levels of aPC, through passive immunization, with polyclonal aPC from pooled human Ig, or with monoclonal aPC. Active immunization with PC is a later possibility. Decreased binding of antithrombotic Annexin V to endothelium is associated with CVD in SLE and potentially in some infectious diseases. Neutralizing antibodies in pooled human Ig restores Annexin V binding and these are thus a therapeutic possibility. Annexin V per se could also prevent CVD.
The CVDIMMUNE combines academic and industrial expertise and objectives, and aims at:
-Investigating novel risk markers for CVD in European patient cohorts of in about 15 000 patients including unique cohorts as the Swedish Twin registry, the MORGAM-study and SLE.
-Investigating immunomodulation as a therapeutic strategy for of CVD.
-Developing documentation for registration of diagnostic ELISA kits in EU and the US.
-Developing proof of concept for at least one pharmaceutical product candidate.
-Providing a strong research foundation and knowledge on mechanisms.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences inflammatory diseases
- medical and health sciences basic medicine immunology immunisation
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences clinical medicine cardiology cardiovascular diseases arteriosclerosis
- medical and health sciences basic medicine immunology autoimmune diseases
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-LIFESCIHEALTH-7
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
STOCKHOLM
Sweden
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.